Xinzhu Wang1, Maddalena Cerrone2, Francesca Ferretti2, Nadia Castrillo2, Gary Maartens3, Myra McClure4, Marta Boffito5. 1. Jefferiss Research Trust Laboratories, Department of Medicine, Imperial College London, London, UK. Electronic address: xinzhu.wang@imperial.ac.uk. 2. St. Stephen's Centre, Chelsea and Westminster Hospital, London, UK. 3. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. 4. Jefferiss Research Trust Laboratories, Department of Medicine, Imperial College London, London, UK. 5. Jefferiss Research Trust Laboratories, Department of Medicine, Imperial College London, London, UK; St. Stephen's Centre, Chelsea and Westminster Hospital, London, UK.
Abstract
BACKGROUND: Tuberculosis (TB) causes 25% of all deaths among individuals infected with human immunodeficiency virus (HIV). Rifampicin (RIF) is a potent inducer of drug metabolizing enzymes and drug transporters, and co-administration with dolutegravir (DTG) reduces DTG exposure; this can be overcome by doubling the DTG dose to 50 mg twice daily. This study investigated the effect of RIF on DTG exposure when dosed at 100 mg once daily, which could provide an easier option than 50 mg twice daily. METHODS: An open label, pharmacokinetic (PK) study was undertaken. Healthy HIV-negative subjects received DTG 50 mg for 7 days (PK1), DTG 100 mg for 7 days (PK2), RIF for 14 days, DTG 50 mg + RIF for 7 days (PK3) and DTG 100 mg + RIF for 7 days (PK4). Steady-state full DTG PK profiles were evaluated. RESULTS: DTG geometric mean ratios (GMRs) of PK3/PK1 of maximum concentration (Cmax), area under curve (AUC24h) and 24-h post-dose concentration (C24h) were 0.65 [90% confidence interval (CI) 0.55-0.75], 0.44 (90% CI 0.37-0.52) and 0.15 (0.13-90% CI 0.17), respectively. GMRs of PK4/PK1 Cmax, AUC24h and C24h were 1.09 (90% CI 0.97-1.21), 0.74 (90% CI 0.64-0.86) and 0.24 (90% CI 0.20-0.28), respectively. Median C24h of DTG 50 mg + RIF and DTG 100 mg + RIF were 251 (range 129-706) ng/mL and 140 (range 73-426) ng/mL, respectively. CONCLUSION: Although there were substantial reductions in DTG C24h when co-administered with RIF, concentrations of both DTG 50 mg and 100 mg once daily with RIF were still above the protein-binding-adjusted IC90 (drug concentration required to inhibit 90% of in-vitro viral replication) of 64 ng/mL. Further studies in HIV-TB co-infected individuals are warranted to confirm these results.
BACKGROUND:Tuberculosis (TB) causes 25% of all deaths among individuals infected with human immunodeficiency virus (HIV). Rifampicin (RIF) is a potent inducer of drug metabolizing enzymes and drug transporters, and co-administration with dolutegravir (DTG) reduces DTG exposure; this can be overcome by doubling the DTG dose to 50 mg twice daily. This study investigated the effect of RIF on DTG exposure when dosed at 100 mg once daily, which could provide an easier option than 50 mg twice daily. METHODS: An open label, pharmacokinetic (PK) study was undertaken. Healthy HIV-negative subjects received DTG 50 mg for 7 days (PK1), DTG 100 mg for 7 days (PK2), RIF for 14 days, DTG 50 mg + RIF for 7 days (PK3) and DTG 100 mg + RIF for 7 days (PK4). Steady-state full DTG PK profiles were evaluated. RESULTS:DTG geometric mean ratios (GMRs) of PK3/PK1 of maximum concentration (Cmax), area under curve (AUC24h) and 24-h post-dose concentration (C24h) were 0.65 [90% confidence interval (CI) 0.55-0.75], 0.44 (90% CI 0.37-0.52) and 0.15 (0.13-90% CI 0.17), respectively. GMRs of PK4/PK1 Cmax, AUC24h and C24h were 1.09 (90% CI 0.97-1.21), 0.74 (90% CI 0.64-0.86) and 0.24 (90% CI 0.20-0.28), respectively. Median C24h of DTG 50 mg + RIF and DTG 100 mg + RIF were 251 (range 129-706) ng/mL and 140 (range 73-426) ng/mL, respectively. CONCLUSION: Although there were substantial reductions in DTG C24h when co-administered with RIF, concentrations of both DTG 50 mg and 100 mg once daily with RIF were still above the protein-binding-adjusted IC90 (drug concentration required to inhibit 90% of in-vitro viral replication) of 64 ng/mL. Further studies in HIV-TB co-infected individuals are warranted to confirm these results.
Authors: Xiaomei I Liu; Jeremiah D Momper; Natella Y Rakhmanina; Dionna J Green; Gilbert J Burckart; Tim R Cressey; Mark Mirochnick; Brookie M Best; John N van den Anker; André Dallmann Journal: Clin Pharmacokinet Date: 2020-11 Impact factor: 6.447
Authors: Aida N Kawuma; Roeland E Wasmann; Kelly E Dooley; Marta Boffito; Gary Maartens; Paolo Denti Journal: Antimicrob Agents Chemother Date: 2022-05-23 Impact factor: 5.938
Authors: Matthew L Romo; Ellen Brazier; Dominique Mahambou-Nsondé; Reneé De Waal; Christine Sekaggya-Wiltshire; Cleophas Chimbetete; Winnie R Muyindike; Gad Murenzi; Cordelia Kunzekwenyika; Thierry Tiendrebeogo; Josephine A Muhairwe; Patricia Lelo; Anastase Dzudie; Christelle Twizere; Idiovino Rafael; Oliver C Ezechi; Lameck Diero; Marcel Yotebieng; Lukas Fenner; Kara K Wools-Kaloustian; N Sarita Shah; Denis Nash Journal: J Int AIDS Soc Date: 2022-07 Impact factor: 6.707
Authors: Kairoonisha Mahomed; Carole L Wallis; Liezl Dunn; Shavani Maharaj; Gary Maartens; Graeme Meintjes Journal: South Afr J HIV Med Date: 2020-07-02 Impact factor: 2.744
Authors: Chi-Hua Lu; Edward M Bednarczyk; Linda M Catanzaro; Alyssa Shon; Jia-Chen Xu; Qing Ma Journal: Curr Res Pharmacol Drug Discov Date: 2021-08-08